Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Graft-versus-Host Disease, Stomatitis

In brief

This study was designed to be conducted in 2 parts. The first part is a pilot study to test the effects of topical thalidomide gel 20mg applied to up to 3 oral ulcers in patients who have developed oral chronic graft-versus-host-disease (cGVHD)-related ulcerative stomatitis following allogeneic bone marrow/peripheral blood stem cell transplant (HSCT). Chronic GVHD may be related to increased levels of a cytokine called TNF-alpha (TNFa) following HSCT. Thalidomide's anti-inflammatory effects may lower TNFa levels, lead to healing of these oral ulcers, and decrease oral pain. If the pilot study is successful, the second part of the study will be done. This will test the effects of a 0.1% (20mg) thalidomide mouthwash in treating oral cGVHD-related stomatitis in patients following allogeneic HSCT. Applying thalidomide directly to the GVHD-related mouth ulcer in gel form or to the entire oral cavity in mouthwash form rather than taking it in pill form may reduce the amount of drug that enters the blood stream and cause less side effects. In the pilot study, participants will be randomly assigned to receive thalidomide gel 20mg or placebo (identical gel with no thalidomide) to use 4 times a day for 4 weeks. In the mouthwash study, participants will be randomly assigned to receive 0.1% 20mg thalidomide mouthwash or placebo (identical mouth rinse with no thalidomide) to use 4 times a day for 4 weeks. Participants will undergo the following procedures before beginning experimental treatment, then once a week for 4 weeks, and then approximately 8 weeks after the first visit: * Interview about current medications and use of alcohol and cigarettes * Self-report of mouth and throat pain * Oral examination for stomatitis rating, and oral ulcer(s) measurement * Quality of life questionnaire (repeated only at week 8 of the study) * Mouth photography to measure and record the oral ulcer response to treatment * Saliva sampling to look for proinflammatory cytokines (small proteins), including TNFa * Oral ulcer exudate collected by filter paper to obtain fluid for measuring TNFa levels * Gentle swabbing of oral ulcers to culture for virus, fungus, and bacteria that may be present * Small punch biopsy of the area near the ulcer or affected area to check for presence of TNFa (repeated only at week 4 of the study) * Blood sampling to monitor TNFa levels * A urine pregnancy test for women who are able to have children (repeated at weeks 2, 4, and 8)

Key facts

Study ID: NCT00075023
Run by: National Institute of Nursing Research (NINR)
People needed: 10
Starts: 2003-12-01
Expected to finish: 2010-04-01
Last updated by the study team: 2015-11-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Pregnant or lactating females;
For the proof of concept study, females who are not surgically sterilized by means of hysterectomy or tubal ligation;
For the main study, females of childbearing potential who do not agree to the use of two forms of highly effective contraception for at least four weeks prior, during, and for four weeks following the last dose of study drug;
Sexually active males who do not agree to the use of a latex condom while receiving study drug and for four weeks following the last dose of study drug;
Unwilling to follow precautions for use of thalidomide;
Unable to demonstrate appropriate use of study medication;
Concurrent use of non-protocol-related medications confounding assessment of the inflammatory response (antihistamines, non-steroidal anti-inflammatory drugs);
Allergic reaction to thalidomide;
Pre-existing oral infection, which might maximize the possibility of an infection or sepsis contributing to a drug-related adverse event;
Unwilling or unable to forego concurrent treatment for mucosal lesions and/or related oral pain (including topical steroids, viscous lidocaine, topical anti-fungals);
Requiring addition of new systemic therapy including thalidomide, steroids, or radiation therapy;
Use of sedatives (including CNS depressants);
Absolute neutrophil count (ANC) less than 750/mm(3)

Where it is running

National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.